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Although magnetic resonance cholangiopancreatogra-
phy (MRCP) provides excellent anatomic detail of the
biliary and pancreatic ducts and has markedly decreased
the application of diagnostic endoscopic retrograde
cholangiopancreatography (ERCP) in recent years,
therapeutic ERCP remains a cardinal intervention for
biliary and pancreatic diseases.1 However, ERCP is still
perceived as the most worrisome procedure in the clin-
ical setting of gastroenterology, especially when one is
confronting a fatal episode of severe post-ERCP pancre-
atitis (PEP). In a recent systematic survey of 21 studies
involving 16,855 patients, the incidences of ERCP-
associated complications and mortality were 6.85% and
0.33%, respectively.2
Increases in serum amylase and lipase activities after
ERCP are common, occurring in about 25–75% of all
patients.3 Acute pancreatitis is a major complication of
ERCP. The incidence of PEP is approximately 1–10%.
Although most PEP (90%) is rated as mild to moder-
ate pancreatitis and does not require specific therapy,
PEP may cause mortality in 0.11% of patients under-
going ERCP.2 Therefore, the pharmacologic preven-
tion of PEP has been an important issue in the past
20 years. From the literature, potential drugs for pre-
vention of PEP include somatostatin, octreotide (a
long-acting somatostatin analog), gabexate mesilate,
nitroglycerin, calcium-channel blocker, N-acetylcysteine,
steroids, nonsteroidal anti-inflammatory drugs (NSAIDs;
indomethacin and diclofenac), allopurinol, interleukin-
10, platelet-activating factor inhibitor, tumor necrosis
factor-α inhibitor, and antibiotics.4 However, after
randomized trials or meta-analyses, most of the drugs
proposed for prophylaxis against PEP have not been
validated.
Although the pathogenesis of acute pancreatitis has
not yet been clarified, the hyperstimulation of exocrine
secretion is one of the main possible causes under dis-
cussion.5 Somatostatin has nonspecific inhibitory actions
on the gut, pancreas and nervous system. Based on
the potent inhibition of pancreatic exocrine secretion,
somatostatin and octreotide may be useful for treat-
ment of acute pancreatitis and prophylaxis against
PEP. Animal trials have shown the beneficial effects of
somatostatin and octreotide in experimental pancreati-
tis; however, the effects of somatostatin and octreotide
for acute pancreatitis and prevention of PEP have been
controversial despite extensive clinical studies.4,6
Several qualified, randomized and placebo-controlled
trials have examined the prophylactic effects of so-
matostatin for PEP.7–13 The results have hitherto been
conflicting. Recently, 2 meta-analyses also showed con-
tradictory results.14,15 The discrepancy may be related
to the heterogeneity of clinical trials with different
dosages and length of somatostatin administration,
and different definitions of PEP. Rudin et al analyzed
7 high-quality studies involving 3,130 patients to
examine the effects of somatostatin and gabexate for
PEP.15 They divided the studies into 3 groups accord-
ing to the length of somatostatin administration: (1)
somatostatin infusion for 12 hours; (2) somatostatin
infusion for less than 12 hours; and (3) somatostatin
as a bolus. They showed that somatostatin given as 
an infusion for 12 hours and as a bolus yielded a sig-
nificant reduction in PEP risk (7.7% and 8.2%) and
rate of hyperamylasemia. They concluded that somato-
statin given as a bolus seemed to be an efficacious and
applicable measure for PEP prevention. In the most
recent randomized, multicenter, and controlled study
by Lee et al, continuous infusion of somatostatin 3 mg
for 12 hours or placebo was given to 391 patients under-
going therapeutic ERCP.7 They confirmed that somato-
statin could significantly reduce the incidence of PEP
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(3.6% vs. 9.6%, p = 0.02). Andriulli et al demonstrated
that short-term administration of somatostatin (2.5
and 6.5 hours) was ineffective for the prevention of
PEP.10,11 The major data from the 7 high-quality clin-
ical trials evaluating the prophylactic effect of somato-
statin for PEP are summarized in Table 1.
In a previous issue of the Journal of the Chinese
Medical Association, Chan et al evaluated the effect 
of somatostatin as a bolus-plus-continuous infusion
for 12 hours and as a bolus alone for prevention of
PEP.16 They recruited 133 patients and found that
there was no significant difference in the incidence of
PEP between the somatostatin groups and the con-
trol group. The incidence of PEP in the somatostatin
groups was 2.5% with a bolus administration and 6.8%
with a bolus-plus-infusion administration as compared
with 4.1% in the control group. Unfortunately, the
study was terminated early due to a higher incidence of
PEP (but not statistically significant) in the group who
received bolus-plus-infusion of somatostatin. Inter-
estingly, the incidences of post-procedure hyperamy-
lasemia in the somatostatin groups with diagnostic
ERCP were lower than that in the control group with
diagnostic ERCP (8% and 21% vs. 47%). Does this
indicate that somatostatin may have a beneficial effect
on pancreatic injury? The limitation of Chan et al’s
study is that the number of patients was not sufficient
to get a conclusive result.16 Further study is required
to clarify the effect of somatostatin given as a bolus
plus an infusion for the prevention of PEP.
The baseline incidence of PEP (in the placebo group)
is a critical factor for determining the sample size of a
trial if it is to end with statistically meaningful data.
The estimated sample sizes are 394 and 821 individuals
with the intent to cut PEP incidence by 50% from the
expected baseline incidences of 10% and 5%, respec-
tively. It is an interesting finding that the baseline PEP
incidence was around 10% in positive studies on the
effect of somatostatin for prevention of PEP and was
around 5% in negative studies (Table 1).7–13,16 A large,
randomized, placebo-controlled, and multicenter study
recruiting around 1,000 patients to validate the effect
of somatostatin may be warranted to end the story.
Multiple risk factors might contribute to the devel-
opment of PEP. These include: (1) procedural factors—
sphincterotomy longer than 2 cm, precut sphinctero-
tomy, pancreatic sphincterotomy, papillary balloon
dilation, sphincter of Oddi manometry, multiple injec-
tions of pancreatic duct, and difficult cannulation; (2)
patient factors—young age, female sex, sphincter of
Oddi dysfunction, and previous PEP; and (3) operator
experience.17 Some factors cannot be predicted before
ERCP. Cost-effectiveness benefit must be considered
in the routine use of prophylactic drugs for PEP. If
high risk for PEP is noted before ERCP, prophylactic
drugs may be administered. If high risk for PEP is
noted after ERCP, pancreatic stent placement may be
considered.18
In conclusion, pharmacologic prevention of PEP
is appealing for gastroenterologists worldwide. In a
review of the literature, somatostatin given as a bolus or
as a continuous infusion over 12 hours appears to be
effective for risk reduction of PEP. The issues regarding
selection of patients at higher risk of PEP and what
constitutes an effective regimen for prophylaxis against
PEP still need to be elucidated by large-scale, high-
quality studies.
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Table 1. Summary of somatostatin trials for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP)
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7 Infusion 3 mg for 12 hr 391 3.6% vs. 9.6% 0.02
10 Infusion 750 μg for 2.5 hr 382 11.5% vs. 6.5% NS
11 Infusion 750 μg for 6.5 hr 746 6.3% vs. 4.8% NS
16 Bolus (250 μg) 89 2.5% vs. 4.1% NS
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